Our lawyers are handling Belviq lawsuits in every 50 states. These pages provides a March 2022 update in these lawsuits and discusses potential settlement amounts and jury payouts for these cases.
May 2022 Belviq Lawsuit Update on Settlement Talks
We should have a worldwide settlement of the Belviq lawsuits in the near future. Joint motions have already been filed in Belviq lawsuits pending in several federal districts requesting the cases to be stayed since the Belviq plaintiffs are negotiating a widespread settlement with defendants Eisai and Arena Pharmaceuticals. Although there's no MDL for the Belviq lawsuits, the terms of the global settlement will probably be very similar.
March 2022 Belviq Lawsuit Update
A federal judge in among the first Belviq colon cancer lawsuits to be filed (Johnson v. Eisai, Inc., et al.) recently rejected an endeavor by the defense to have the plaintiffs'case dismissed. The defendants had filed a motion seeking dismissal of nearly all of the plaintiffs'claims in the case.
But Judge Carmen Henderson (N.D. Ohio) denied the absolute most significant areas of that motion. Although dismissal was granted regarding the claims for design defect, and punitive damages, the plaintiffs'principal claims (including negligent failure to warn) will proceed. What's Belviq?
Belviq may be the brand name for Lorcaserin, a brand new kind of hormone appetite suppressant medication developed for the treating obesity. It had been originally produced by Arena Pharmaceuticals and later manufactured and sold by Japanese-based pharmaceutical company Eisai.
The FDA approved Belviq in June 2012. Belviq was designed to complement a reduced-calorie diet and physical activity. It worked by suppressing one's appetite. The drug came in two forms: a 10 mg tablet to be studied twice a day and a 20 mg extended-release tablet, named Belviq XR, to be used once a day.